The growing demand for POC tests for the diagnosis of healthcare-associated infections (HAIs) will have a positive impact on the growth of the market
The global healthcare-associated infectious disease diagnostics market size to reach USD 5.4 billion by 2024 growing at a CAGR of over 8% during the forecast period. The application of molecular diagnostics, especially for HAIs, has steadily progressed from research-based highly complex tests to widespread adoption by a diverse range of end-users. While traditional techniques are being challenged, the development of molecular diagnostic tests offers a variety of advantages such as high accuracy and specificity and perform multiple tests in a single instance. Molecular diagnostics will become a critical part of hospital-acquired infections testing, especially in the battle against antibiotic resistance. Hence, the adoption of molecular diagnostics is likely to increase at a significant rate due to its high sensitivity, specificity, and accuracy, as well as the capability to deliver results quickly. This adoption of molecular diagnostic testing will have a positive impact on the growth of the overall healthcare-associated infections diagnostics market in the coming years.
The dynamics of the healthcare sector is changing due to ongoing healthcare reforms, increasing economic expenditure, and growing recognition that healthcare services need to be less fragmented and more patient-centric. Point-of-care (POC) diagnostics testing is perceived as one of the ways to achieve patient-centric healthcare and cost-effective treatment for patients. POC tests offer significant benefits over the traditional lab-based tests for diagnosing HAIs. For instance, patients admitted in ICUs and neonates in neonatal intensive care could be benefitted as the test could be performed at the bedside, and immediate results can be obtained. Therefore, the growing demand for POC tests for the diagnosis of HAIs will have a positive impact on the growth of the market during the forecast period. The healthcare-associated infectious disease diagnostics market is expected to grow at a CAGR of over 8% during the period 2018–2024.
HEALTHCARE-ASSOCIATED INFECTIONS DIAGNOSTICS MARKET SEGMENTATION
This research report includes detailed market segmentation by
INSIGHTS BY PRODUCTS
The growing awareness of HAIs worldwide is one of the key factors fueling the growth of the consumable segment
The usage of a wide array of reagents and test kits to perform diagnostic tests for diagnosing several HAIs in healthcare settings is a major factor for the growth of the consumables segment. Also, the growing awareness of HAIs worldwide is one of the key factors fueling the growth of the consumable segment. The consumables segment is growing due to the increasing usage of several microbial culture tests, urinalysis, immunoassay tests, and PCR tests in several healthcare settings for diagnosing infectious diseases.
The analyzer segment is growing at a relatively slower pace than the consumables segment as it is capital intensive, and purchasing decisions for analyzers depend on financial resources and budget allocations. However, analyzers used in molecular diagnostic tests and at POC sites are growing at a relatively higher growth rate than clinical laboratory analyzers as end-users are preferring analyzers with high sensitivity and delivering highly accurate results with less turnaround time.
INSIGHTS BY INFECTIONS
Urinary tract infections account for 35−40% of nosocomial infections and occupy the largest share in the overall HAIs category
Urinary tract infections (UTI) account for 35−40% of all nosocomial infections and occupy the largest share in the overall HAIs category. The prevalence of hospital-acquired UTIs is continuously increasing globally. Several technological advancements have enhanced the testing procedures for hospital-acquired UTIs. New diagnostic platforms have improved the accuracy and speed of pathogen identification from primary cultures. The market is likely to grow at a CAGR of 9% during the forecast period.
Surgical site infections are the most common complications following major gastrointestinal surgeries, affecting between 25 and 40% of patients. The surgical site infections (SSI) segment is growing at a steady rate and is likely to grow at a similar pace during the forecast period. SSIs remain a significant clinical challenge as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources.
The prevalence of hospital-acquired pneumonia (HAP) and related deaths is increasing at an alarming rate worldwide. Therefore, there is an increased emphasis on minimizing the occurrence of HAP in healthcare settings. The market is expected to witness fast growth in the coming years due to the development and commercialization of advanced nucleic acid detection tests and advancements in POC testing products for pneumonia. Further, the growing awareness of the benefits of a quick diagnosis of HAP is increasing the demand for HAP diagnostic tests both in developed and developing countries. The segment is expected to grow at a CAGR of over 9% during the forecast period.
INSIGHTS BY TESTS
The market is witnessing widespread uptake of POC diagnostic tests for the diagnosis of several infections in several healthcare settings
The traditional diagnostics segment is growing at a moderate rate. A reliable and accurate diagnosis of HAIs is of utmost importance in healthcare settings. Traditional diagnostic tests are considered as the gold-standard and are widely used to diagnose HAIs. The healthcare-associated infections diagnostics market is witnessing widespread uptake of POC diagnostic tests for the diagnosis of several infections in several healthcare settings such as acute and ambulatory healthcare settings. Therefore, there is a growing need for highly efficient and automated diagnostic tests for diagnosing HAIs, especially antibiotic-resistant microbes.
The molecular diagnostics market segment is growing at a faster rate than the traditional diagnostics segment. This growth can be attributed to multiple advantages and clinically proven superior efficacy of molecular diagnostic tests. The increasing availability of automated and compact analyzers has significantly improved the efficiency and quality of end-user operations. These automated analyzers are designed to meet the high demand for quality diagnostic testing.
INSIGHTS BY END-USERS
Developing countries are 20 times more prone to HAIs risk than developed countries
Hospitals are the major source for HAIs, and many hospitalized patients acquire several pathogenic and non-pathogenic infections during the stay. Most hospitals report central line-associated bloodstream infections, catheter-associated UTIs, and SSIs following surgeries such as heart, abdominal hysterectomy, colon, and knee surgical procedures. The adoption of diagnostic testing for healthcare-associated infections is steadily increasing globally to tackle adverse events related to HAIs and take appropriate decisions on treatments. Therefore, the increase in the number of people with HAIs is encouraging physicians in hospitals to use advanced and rapid diagnostic tests, thereby contributing to the growth of the segment.
Healthcare-associated infections are no longer confined to hospitals. Small and medium-sized clinics, physician offices, and solo practitioners are non-adherent to recommended infection prevention and control procedures. Developing countries have reported 20 times more HAIs risk in clinics than in developed countries. The rapid emergence and prevalence of community-associated infections caused by resistant microbes has been recognized to cause serious infections among patients. Therefore, the high risk of HAIs in clinics and ASCs is expected to drive the healthcare-associated infections diagnostics market.
INSIGHTS BY GEOGRAPHY
The increased uptake of molecular diagnostic testing for diagnosing HAIs is a key reason for the significant market growth
The healthcare-associated infections diagnostics market in North America is likely to witness upward growth in terms of revenue, with key vendors focusing on developing innovative and advanced infectious disease diagnostics products, which will offer efficient results. The US is the major revenue contributor to the global market due to the presence of health coverage and the availability of advanced health infrastructure. With the growing demand for diagnostic devices for HAIs, vendors are focusing on introducing innovative products to cater to the growing demand for advanced diagnostic techniques for HAIs in the US.
Europe accounts for the second-highest market share in the global healthcare-associated infections diagnostics market. Countries such as Germany, France, the UK, Spain, Italy, and Denmark have a high occurrence rate of HAIs. According to the European Centre for Disease Control and Prevention (ECDC), approximately 9 million HAI cases occur across Europe annually. The increased uptake of molecular diagnostic testing for diagnosing HAIs is a key reason for the significant market growth. Germany is the largest healthcare-associated infectious disease diagnostics market in Europe. The presence of a large patient pool, better accessibility to diagnostics services, and established healthcare delivery are contributing to the growth of the market in the country.
The growing demand for traditional culture-based tests and immunoassays is a major driver for the APAC market. Further, the low-cost nature and limited resource availability of performing advanced molecular tests is driving the APAC market. The frequency of ICU-acquired infections is at least 2─3 times higher in low- and middle-income countries than in high-income countries. This can be attributed to poor hygiene practices and the lack of stringent regulatory controls. Newborns are the most vulnerable population for HAIs and are at higher risk of acquiring the healthcare-associated infection in developing countries, with 3 to 20 times higher than in high-income countries.
INSIGHTS BY VENDORS
The healthcare-associated infections diagnostics market is consolidated and is characterized by the presence of several active global, regional, and local players, offering a diverse range of diagnostic analyzers and consumables for diagnosing HAIs. Global players are focusing on developing innovative products and expanding their product portfolio to remain competitive in the market. They are investing extensively in R&D and product development activities to expand their product portfolio. Key players are also engaged in strategic acquisitions as part of the inorganic growth strategy to improve sales and profit margins. Strategic M&As continue to be an important competitive strategy for key players to expand product offerings, access new technology, or increase market share.
The Healthcare-associated Infectious Disease Diagnostics market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:
Market Segmentation by Products
- Diagnostic Analyzers/Instruments
Market Segmentation by Infections
- Urinary Tract Infections Hospitals
- Surgical Site Infections
- Hospital-acquired Pneumonia
- Blood Stream Infections
- Other Healthcare-associated Infections
Market Segmentation by End-users
- Specialty Orthopedic and Spine Centers
Market Segmentation by Diagnostic Tests
- Traditional Diagnostics
- Molecular Diagnostics
Market Segmentation by Geography
- North America
- South Korea
- Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa